Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of
Primary Immunodeficiency Diseases and Neurological Disorders
Stimulate Market Growth
Published on September 2011

Report Summary

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological
Disorders Stimulate Market Growth

Summary

GBI Research's report, 'Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases
and Neurological Disorders Stimulate Market Growth' provides in-depth analysis of the, drivers and barriers that affect the global
immunoglobulins market. The report analyzes the markets for immunoglobulins products in the US, the top five countries in Europe
(the UK, Germany, France, Italy and Spain) and Japan. Epidemiology, revenue, and annual cost of therapy are forecast until 2017 for
the key geographies as well as seven key therapeutic segments. The report also provides profiles for the leading companies and
analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Scope

The scope of this report includes -
- Annualized market data for the immunoglobulins market from 2002 to 2010, and forecast to 2017.
- Analysis of the seven key therapeutic segments. These include PID, CIDP, multifocal motor neuropathy, myasthenia gravis, chronic
lymphocytic leukemia, guillain-barre syndrome and idiopathic thrombocytopenic purpura.
- Analysis of the immunoglobulins markets in the leading geographies of the world, which include the US, the top five countries in
Europe and Japan.
- Market characterization of the immunoglobulins (PID, CIDP, multifocal motor neuropathy, myasthenia gravis, chronic lymphocytic
leukemia, guillain-barre syndrome and idiopathic thrombocytopenic purpura) market, including market size, revenue analysis by the
top seven geographies, annual cost of therapy, and epidemiology.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of the pipeline molecules in various phases of drug development.
- Competitive profiling of the leading companies. The key companies studied in this report are Baxter International Inc., Biotest, Bio
Products Laboratory Ltd., CSL Behring LLC, Kedrion, LFB, Octapharma, Talecris, and Grifols.
- Key M&A activities and licensing agreements between 2004 and 2011 in the global immunoglobulins market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets
poised for strong growth.
- Develop key strategic initiatives by understanding the key focus areas of the leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth (From Slidesha Page 1/11
re)


Table of Content

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 9
2 Global Immunoglobulins Market: Introduction 11
2.1 Overview 11
2.2 GBI Research Report Guidance 12
3 Global Immunoglobulins Market: Market Overview 13
3.1 Introduction 13
3.1.1 Rising Demand for Immunoglobulins Attributed to New Indications 14
3.1.2 On-Label Uses versus Off-Label Uses in the US 15
3.1.3 IVIG vs. SCIG Usage 15
3.2 Revenue Forecasts for the Global Immunoglobulins Market 16
3.3 Annual Cost of Therapy 18
3.4 Immunoglobulins Market Drivers and Restraints 19
3.4.1 Immunoglobulins Market Drivers 20
3.4.2 Immunoglobulins Market Restraints 20
4 Global Immunoglobulins Market: Geographical Landscape 21
4.1 Geographical Break-up 21
4.1.1 The US 22
4.1.2 Top Five Countries in Europe 24
4.1.3 Japan 27
5 Global Immunoglobulins Market: Therapeutic Landscape 29
5.1 Primary Immunodeficiency 29
5.1.1 Introduction 29
5.1.2 Revenue 30
5.1.3 Annual Cost of Therapy 32
5.1.4 Epidemiology 33
5.1.5 Current Use 36
5.1.6 Geographical Segmentation 37
5.2 Guillain-Barré Syndrome Market 39
5.2.2 Revenue 40
5.3 Chronic Lymphocytic Leukemia Market 47
5.3.2 Revenue 48

re)


5.4 Chronic Inflammatory Demyelinating Polyneuropathy Market 56
5.4.2 Revenue 57
5.5 Myasthenia Gravis Market 63
5.5.2 Revenue 64
5.6 Multifocal Motor Neuropathy Market 70
5.6.2 Revenue 71
5.7 Idiopathic Thrombocytopenic Purpura 79
5.7.2 Revenue 80
5.7.5 Current Use of Immunoglobulins and Other Therapies 85
6 Global Immunoglobulins Market: Pipeline Analysis 87
6.1 Research and Development Pipeline ' CIDP 87
6.2 Research and Development Pipeline ' PID 87
6.3 Research and Development Pipeline ' GBS 88
6.4 Research and Development Pipeline ' ITP 88
6.5 Research and Development Pipeline ' Myasthenia Gravis 88
6.6 Research and Development Pipeline ' Multifocal Motor Neuropathy 88
6.7 Research and Development Pipeline ' CLL 88
7 Global Immunoglobulins Market: Profiles of Marketed Products 89
7.1 Privigen 89
7.1.1 Overview 89
7.1.2 Approved Indications 89
7.1.3 Safety 89
7.1.4 Efficacy 89
7.1.5 Clinical Study Details 90
7.2 Gammagard S/D 90
7.2.1 Overview 90

re)


7.2.3 Safety 91
7.2.4 Efficacy 91
7.3 Gammagard Liquid 91
7.3.1 Overview 91
7.3.3 Safety 92
7.3.4 Efficacy 92
7.4 Octagam 5% 92
7.4.1 Overview 92
7.4.3 Safety 93
7.4.4 Efficacy 93
7.5 Flebogamma 5% 93
7.5.1 Overview 93
7.5.2 Safety 93
7.5.3 Efficacy 94
7.6 Flebogamma 10% 94
7.6.1 Overview 94
7.6.2 Safety 94
7.6.3 Efficacy 94
7.7 Gamunex 95
7.7.1 Overview 95
7.7.2 Safety 95
7.7.3 Efficacy 95
7.8 Gammaplex 96
7.8.1 Overview 96
7.8.2 Safety 96
7.8.3 Efficacy 97
7.9 Vivaglobin 97
7.9.1 Overview 97
7.9.2 Safety 97
7.9.3 Efficacy 97
7.10 Hizentra 98
7.10.1 Overview 98
7.10.2 Safety 98
7.10.3 Efficacy 98
7.11 Pentaglobin 98
7.11.1 Overview 98
7.11.2 Efficacy 98
7.11.3 Safety 99
7.12 Tegeline 99
7.12.1 Overview 99
7.12.2 Efficacy in multifocal motor neuropathy 99
7.12.3 Safety in multifocal motor neuropathy 99
7.12.4 Efficacy in CIDP 99
7.12.5 Safety in CIDP 99

re)


8 Global Immunoglobulins Market: Competitive Landscape 100
8.1 Market Share Analysis: Immunoglobulins 100
8.2 Baxter International Inc. 101
8.2.1 Business Description 101
8.2.2 SWOT Analysis 101
8.3 Biotest 102
8.4 Bio Products Laboratory Ltd. 103
8.5 CSL Behring LLC 103
8.6 Kedrion S.p.A. 104
8.7 LFB S.A. 105
8.8 Octapharma AG 106
8.9 Talecris Biotherapeutics Holdings Corp 107
8.10 Grifols S.A. 108
9 Global Immunoglobulins Market: M&A and Licensing Deals Landscape 109
9.1 Overview 109
9.2 R&D Licensing Agreements 112
9.2.1 Kedrion Signs Up With Prometic for Access to the Latter's Technologies to Manufacture Hyperimmunes in Europe 112
9.2.2 WIBP Enters Into Licensing Agreement with Prometic for the Latter's PPP System to Produce Plasma-Derived Products in
China 112
9.3 Co-Development Agreements 113
9.3.1 Baxter Collaborates With Halozyme Baxter for a Subcutaneous Route of Administration of GAMMAGARD LIQUID 10% 113
10 Global Immunoglobulins Market: Appendix 114
10.1 Market Definitions 114
10.2 Abbreviations 114
10.3 Research Methodology 116
10.3.1 Coverage 116
10.3.2 Secondary Research 116
10.3.3 Primary Research 117
10.3.4 Therapeutic Landscape 117
10.3.5 Market Size by Geography 119
10.3.6 Geographical Landscape 120
10.3.7 Pipeline Analysis 120

re)


10.3.8 Competitive Landscape 120
10.3.9 Expert Panel Validation 120
10.4 Contact Us 120
10.5 Disclaimer 121
10.6 Sources 1211.1 List of Tables
Table 1: Immunoglobulins Market, Global, Consumption of IVIG, 1990-2006 14
Table 2: Immunoglobulins Market, Global, Consumption of IVIG, 2006-2016 14
Table 3: Immunoglobulins Market, Global, Revenue ($m), 2002-2010 17
Table 4: Immunoglobulins Market, Global, Revenue ($m), 2010-2017 17
Table 5: Immunoglobulins Market, Global, Annual Cost of Therapy ($), 2002-2010 19
Table 6: Immunoglobulins Market, Global, Annual Cost of Therapy ($), 2010-2017 19
Table 7: Immunoglobulins Market, The US, Revenue ($m), 2002-2010 22
Table 8: Immunoglobulins Market, The US, Revenue ($m), 2010-2017 22
Table 9: Immunoglobulins Market, The US, Annual Cost of Therapy ($), 2002-2010 23
Table 10: Immunoglobulins Market, The US, Annual Cost of Therapy ($), 2010-2017 23
Table 11: Immunoglobulins Market, Top Five Countries in Europe, Revenue, ($m), 2002-2010 24
Table 12: Immunoglobulins Market, Top Five Countries in Europe, Revenue, ($m), 2010-2017 25
Table 13: Immunoglobulins Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010 26
Table 14: Immunoglobulins Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 26
Table 15: Immunoglobulins Market, Japan, Revenue ($m), 2002-2010 27
Table 16: Immunoglobulins Market, Japan, Revenue ($m), 2010-2017 27
Table 17: Immunoglobulins Market, Japan, Annual Cost of Therapy, ($), 2002-2010 28
Table 18: Immunoglobulins Market, Japan, Annual Cost of Therapy, ($), 2010-2017 28
Table 19: Immunoglobulins Market, Global, Primary Immunodeficiency, Revenue ($m), 2002-2010 30
Table 20: Immunoglobulins Market, Global, Primary Immunodeficiency, Revenue ($m), 2010-2017 30
Table 21: Immunoglobulins Market, Global, Primary Immunodeficiency, Annual Cost of Therapy ($), 2002-2010 32
Table 22: Immunoglobulins Market, Global, Primary Immunodeficiency, Annual Cost of Therapy ($), 2010-2017 32
Table 23: Immunoglobulins Market, Global, Primary Immunodeficiency, Epidemiology, 2002-2010 34
Table 24: Immunoglobulins Market, Global, Primary Immunodeficiency, Epidemiology, 2010-2017 34
Table 25: Immunoglobulins Market, Global, Primary Immunodeficiency, Geographical Segmentation of Revenue, ($m), 2002-2010 37
Table 26: Immunoglobulins Market, Global, Primary Immunodeficiency, Geographical Segmentation of Revenue, ($m), 2010-2017 38
Table 27: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Revenue ($m), 2002-2010 40
Table 28: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Revenue ($m), 2010-2017 40
Table 29: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Annual Cost of Therapy ($), 2002-2010 41
Table 30: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Annual Cost of Therapy ($), 2010-2017 41
Table 31: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Epidemiology, 2002-2010 42
Table 32: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Epidemiology, 2010-2017 43
Table 33: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Geographical Segmentation of Revenue, ($m), 2002-2010 46
Table 34: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Geographical Segmentation of Revenue, ($m), 2010-2017 46
Table 35: Immunoglobulins Market, Global, CLL, Revenue, ($m), 2002-2010 48
Table 36: Immunoglobulins Market, Global, CLL, Revenue ($m), 2010-2017 48
Table 37: Immunoglobulins Market, Global, CLL, Annual Cost of Therapy ($), 2002-2010 49
Table 38: Immunoglobulins Market, Global, CLL, Annual Cost of Therapy ($), 2010-2017 49
Table 39: Immunoglobulins Market, Global, CLL, Epidemiology, ('000), 2002-2010 50
Table 40: Immunoglobulins Market, Global, CLL, Epidemiology, ('000), 2010-2017 51
Table 41: Immunoglobulins Market, Global, CLL, Geographical Segmentation of Revenue, ($m), 2002-2010 55
Table 42: Immunoglobulins Market, Global, CLL, Geographical Segmentation of Revenue, ($m), 2010-2017 56
Table 43: Immunoglobulins Market, Global, CIDP, Revenue, ($m), 2002-2010 57

re)


Table 44: Immunoglobulins Market, Global, CIDP, Revenue ($m), 2010-2017 57
Table 45: Immunoglobulins Market, Global, CIDP, Annual Cost of Therapy ($), 2002-2010 58
Table 46: Immunoglobulins Market, Global, CIDP, Annual Cost of Therapy ($), 2010-2017 58
Table 47: Immunoglobulins Market, Global, CIDP, Epidemiology ('000), 2002-2010 59
Table 48: Immunoglobulins Market, Global, CIDP, Epidemiology ('000), 2010-2017 60
Table 49: Immunoglobulins Market, Global, CIDP, Geographical Segmentation of Revenue, ($m), 2002-2010 62
Table 50: Immunoglobulins Market, Global, CIDP, Geographical Segmentation of Revenue, ($m), 2010-2017 63
Table 51: Immunoglobulins Market, Global, Myasthenia Gravis, Revenue, ($m), 2002-2010 64
Table 52: Immunoglobulins Market, Global, Myasthenia Gravis, Revenue ($m), 2010-2017 64
Table 53: Immunoglobulins Market, Global, Myasthenia Gravis, Annual Cost of Therapy ($), 2002-2010 65
Table 54: Immunoglobulins Market, Global, Myasthenia Gravis, Annual Cost of Therapy ($), 2010-2017 65
Table 55: Immunoglobulins Market, Global, Myasthenia Gravis, Epidemiology, 2002-2010 66
Table 56: Immunoglobulins Market, Global, Myasthenia Gravis, Epidemiology, 2010-2017 67
Table 57: Immunoglobulins Market, Global, Myasthenia Gravis, Geographical Segmentation of Revenue, ($m), 2002-2010 69
Table 58: Immunoglobulins Market, Global, Myasthenia Gravis, Geographical Segmentation of Revenue, ($m), 2010-2017 70
Table 59: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Revenue, ($m), 2002-2010 71
Table 60: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Revenue ($m), 2010-2017 71
Table 61: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Annual Cost of Therapy ($), 2002-2010 72
Table 62: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Annual Cost of Therapy ($), 2010-2017 73
Table 63: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Epidemiology, 2002-2010 75
Table 64: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Epidemiology, 2010-2017 75
Table 65: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Geographical Segmentation of Revenue, ($m), 2002-2010
78
Table 66: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Geographical Segmentation of Revenue, ($m), 2010-2017
79
Table 67: Immunoglobulins Market, Global, ITP, Revenue, ($m), 2002-2010 80
Table 68: Immunoglobulins Market, Global, ITP, Revenue ($m), 2010-2017 80
Table 69: Immunoglobulins Market, Global, ITP, Annual Cost of Therapy ($), 2002-2010 81
Table 70: Immunoglobulins Market, Global, ITP, Annual Cost of Therapy ($), 2010-2017 82
Table 71: Immunoglobulins Market, Global, ITP, Epidemiology, 2002-2010 83
Table 72: Immunoglobulins Market, Global, ITP, Epidemiology, 2010-2017 83
Table 73: Immunoglobulins Market, Global, ITP, Geographical Segmentation of Revenue, ($m), 2002-2010 86
Table 74: Immunoglobulins Market, Global, ITP, Geographical Segmentation of Revenue, ($m), 2010-2017 86
Table 75: Immunoglobulins Market, Global, R&D Pipeline in CIDP Market, 2011 87
Table 76: Immunoglobulins Market, Global, R&D Pipeline in CIDP Market, 2011 87
Table 77: Immunoglobulins Market, Global, R&D Pipeline in ITP Market, 2011 88
Table 78: Immunoglobulins Market, Global, R&D Pipeline in Myasthenia Gravis Market, 2011 88
Table 79: Immunoglobulins Market, Global, R&D Pipeline in Multifocal Motor Neuropathy Market, 2011 88
Table 80: Immunoglobulins Market, Global Major M&A Deals, 2004-2010 110
Table 81: Immunoglobulins Market, Global Licensing Deals, 2008 112
Table 82: Immunoglobulins Market, Global Co-Developments, 2005-2007 1131.2 List of Figures
Figure 1: Immunoglobulins Market, Global, Consumption of IVIG, 1990-2016 14
Figure 2: Immunoglobulins Market, Global, Revenue ($m), 2002-2017 17
Figure 3: Immunoglobulins Market, Global, Annual Cost of Therapy ($), 2002-2017 18
Figure 4: Immunoglobulins Market, Global, Drivers and Restraints 19
Figure 5: Immunoglobulins Market, Geographical Break-Up, Revenue (%), 2010-2017 21
Figure 6: Immunoglobulins Market, The US, Revenue ($m), 2002-2017 22
Figure 7: Immunoglobulins Market, The US, Annual Cost of Therapy ($), 2002-2017 23

re)


Figure 8: Immunoglobulins Market, Top Five Countries in Europe, Revenue ($m), 2010-2017 24
Figure 9: Immunoglobulins Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017 26
Figure 10: Immunoglobulins Market, Japan, Revenue, ($m), 2010-2017 27
Figure 11: Immunoglobulins Market, Japan, Annual Cost of Therapy, ($), 2010-2017 28
Figure 12: Immunoglobulins Market, Global, Primary Immunodeficiency, Revenue ($m), 2002-2017 30
Figure 13: Immunoglobulins Market, Global, Primary Immunodeficiency, Annual Cost of Therapy ($), 2002-2017 32
Figure 14: Immunoglobulins Market, Global, Primary Immunodeficiency, Epidemiology ('000), 2002-2017 33
Figure 15: Immunoglobulins Market, Global, Primary Immunodeficiency, Geographical Segmentation of Revenue, ($m), 2002-2017 37
Figure 16: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Revenue ($m), 2002-2017 40
Figure 17: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Annual Cost of Therapy ($), 2002-2017 41
Figure 18: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Epidemiology ('000), 2002-2017 42
Figure 19: Immunoglobulins Market, Global, Guillain-Barré Syndrome, Geographical Segmentation of Revenue, ($m), 2002-2017 45
Figure 20: Immunoglobulins Market, Global, CLL, Revenue, ($m), 2002-2017 48
Figure 21: Immunoglobulins Market, Global, CLL, Annual Cost of Therapy ($), 2002-2017 49
Figure 22: Immunoglobulins Market, Global, CLL, Epidemiology ('000), 2002-2017 50
Figure 23: Immunoglobulins Market, Global, CLL, Geographical Segmentation of Revenue, ($m), 2002-2017 55
Figure 24: Immunoglobulins Market, Global, CIDP, Revenue, ($m), 2002-2017 57
Figure 25: Immunoglobulins Market, Global, CIDP, Annual Cost of Therapy ($), 2002-2017 58
Figure 26: Immunoglobulins Market, Global, CIDP, Epidemiology ('000), 2002-2017 59
Figure 27: Immunoglobulins Market, Global, CIDP, Geographical Segmentation of Revenue, ($m), 2002-2010 62
Figure 28: Immunoglobulins Market, Global, Myasthenia Gravis, Revenue, ($m), 2002-2017 64
Figure 29: Immunoglobulins Market, Global, Myasthenia Gravis, Annual Cost of Therapy ($), 2002-2017 65
Figure 30: Immunoglobulins Market, Global, Myasthenia Gravis, Epidemiology ('000), 2002-2017 66
Figure 31: Immunoglobulins Market, Global, Myasthenia Gravis, Geographical Segmentation of Revenue, ($m), 2002-2017 69
Figure 32: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Revenue, ($m), 2002-2017 71
Figure 33: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Annual Cost of Therapy ($), 2002-2017 72
Figure 34: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Epidemiology ('000), 2002-2017 74
Figure 35: Immunoglobulins Market, Global, Multifocal Motor Neuropathy, Geographical Segmentation of Revenue, ($m), 2002-2017
78
Figure 36: Immunoglobulins Market, Global, ITP, Revenue, ($m), 2002-2017 80
Figure 37: Immunoglobulins Market, Global, ITP, Annual Cost of Therapy ($), 2002-2017 81
Figure 38: Immunoglobulins Market, Global, ITP, Epidemiology ('000) 2002-2017 82
Figure 39: Immunoglobulins Market, Global, ITP, Geographical Segmentation of Revenue, ($m), 2002-2017 85
Figure 40: Immunoglobulins Market, Global, Market Share on the Basis of Revenue, (%), 2010 100
Figure 41: Immunoglobulins Market, SWOT Analysis of Baxter, 2010 101
Figure 42: Immunoglobulins Market, SWOT Analysis for Biotest, 2010 102
Figure 43: Immunoglobulins Market, SWOT Analysis for Bio Products Laboratory Limited, 2010 103
Figure 44: Immunoglobulins Market, SWOT Analysis of CSL Behring, 2010 104
Figure 45: Immunoglobulins Market, SWOT Analysis of Kedrion, 2010 105
Figure 46: Immunoglobulins Market, SWOT Analysis of LFB, 2010 105
Figure 47: Immunoglobulins Market, SWOT Analysis of Octapharma, 2010 106
Figure 48: Immunoglobulins Market, SWOT Analysis of Talecris, 2010 107
Figure 49: Immunoglobulins Market, SWOT Analysis of Grifols, 2010 108
Figure 50: Immunoglobulins Market, Global Strategic Consolidations Landscape, By Deal Type, 2004-2010 109
Figure 51: GBI Research Market Forecasting Model 119

Companies mentioned
Baxter International Inc.

re)


Biotest
Bio Products Laboratory Ltd.
CSL Behring LLC
Kedrion S.p.A.
LFB S.A.
Octapharma AG
Talecris Biotherapeutics Holdings Corp
Grifols S.A.

re)

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurol
ogical Disorders Stimulate Market Growth

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 3 500.00 Quantity: _____

Site License--USD 7 000.00 Quantity: _____

Corporate License--USD 10 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________

re)

Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93

re)

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth